• Profile
Close

Faecal lactoferrin and calprotectin in patients with Clostridium difficile infection: A case–control study

European Journal of Clinical Microbiology & Infectious Diseases Nov 18, 2017

Barbut F, et al. - Researchers here determined the utility of quantifying faecal lactoferrin and calprotectin concentrations in Clostridium difficile infection (CDI) patients with or without free toxins in the stools. Findings revealed that in patients with CDI, both faecal calprotectin and lactoferrin were higher. This was particularly evident in those with detectable toxin in faeces. Thus suggesting a correlation between intestinal inflammation and toxins in stools.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay